Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Receivables (2017 - 2025)

Historic Receivables for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $19.2 million.

  • Innate Pharma's Receivables fell 4790.15% to $19.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $19.2 million, marking a year-over-year decrease of 4790.15%. This contributed to the annual value of $16.3 million for FY2024, which is 7730.18% down from last year.
  • Innate Pharma's Receivables amounted to $19.2 million in Q2 2025, which was down 4790.15% from $16.1 million recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's Receivables peaked at $71.2 million during Q4 2023, and registered a low of $16.1 million during Q4 2024.
  • Moreover, its 5-year median value for Receivables was $54.3 million (2021), whereas its average is $48.3 million.
  • In the last 5 years, Innate Pharma's Receivables soared by 3299.34% in 2023 and then tumbled by 7746.97% in 2024.
  • Innate Pharma's Receivables (Quarter) stood at $56.1 million in 2021, then dropped by 4.54% to $53.6 million in 2022, then soared by 32.99% to $71.2 million in 2023, then tumbled by 77.47% to $16.1 million in 2024, then grew by 19.79% to $19.2 million in 2025.
  • Its Receivables stands at $19.2 million for Q2 2025, versus $16.1 million for Q4 2024 and $36.9 million for Q2 2024.